ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1234

Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity

Jaqueline de amorim1, Simone Kishimoto1, Paula Fernandes1, Roberto Marini2, Zahi Touma3, Hermine Brunner4 and Simone Appenzeller1, 1UNICAMP, Campinas, Brazil, 2Revista Brasileira de Reumatologia, Campinas, Brazil, 3University of Toronto, Toronto, ON, Canada, 4Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH

Meeting: ACR Convergence 2023

Keywords: neuropsychiatric disorders, Neuropsychological Assessment, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The purpose of this study was to (1) Explore and test Cognitive Performance Score (CPS) in childhood-onset systemic lupus erythematosus (cSLE). (2) Compare different CPS scores between cSLE and to determine if there is an association with disease activity.

Methods: Consecutive cSLE and healthy controls responded to the PedAnam. We performed the calculation of four scores: (1) PedANAM-CPSUWA using unweighted averages of the accuracy score; (2) PedANAM-CPSPCA principal component analysis; (3) PedANAM-CPSlogit used logistic regression; (4)PedANAM-CPSmultiscore logistic models based on performance parameters with selected subtests. After these calculations, we observed the correlation between the CPS indices and compared the performance of patients and healthy controls. Cognitive impairment was determined by z-scores and considered present if ≤2 SD from healthy controls. Disease activity was evaluated through SLE disease activity score and cutoff of 3 was considered active disease.

Results: We included a total of 50 consecutive cSLE (45 [90%] women; median age = 14 years; age range = 9–18 years) and 50 healthy controls (44 [88 %] women; median age = 15; age range = 9-18 years). We observed a correlation between the PedANAM-CPSUWA and the PedANAM-CPSPCA (r = 0.99), PedANAM-CPSPCA and PedANAM-CPSmultiscore (r = -0.60) logit and PedANAM-CPSUWA (r = -0.56). We observed statistically significant differences between patients and healthy controls in the PedANAM-CPSUWA and PedANAM-CPSPCA scores (P = 0.001). Cognitive impairment was observed in12 (24%) cSLE patients and 1 (2%) healthy controls (p < 0.001) by the PedANAM-CPSUWA index and using the PedANAM-CPSPCA index. An association between disease activity and PedANAM-CPSUWA index (p=0.01) and PedANAM-CPSPCA index (p=0.002) was observed.

Conclusion: After the translation and validation process, this is the first study using the CPS in Brazilian version of PedANAM and we identified two of the metrics that were able to differentiate between cSLE and healthy controls. Worse performance with disease activity was observed. Funding FAPESP (CEPID BRAINN 13/07559-3)


Disclosures: J. de amorim: None; S. Kishimoto: None; P. Fernandes: None; R. Marini: None; Z. Touma: AstraZeneca, 2, GSK, 2; H. Brunner: AbbVie, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb (BMS), 2, 5, Celgene, 2, Eli Lilly, 2, 5, EMD Serono, 2, F-Hoffman La Roche, 2, 5, GlaxoSmithKlein (GSK), 2, 5, 6, Horizon, 2, 2, Janssen, 5, Merck, 2, Novartis, 2, 5, 6, Pfizer, 2, 5, 6; S. Appenzeller: None.

To cite this abstract in AMA style:

de amorim J, Kishimoto S, Fernandes P, Marini R, Touma Z, Brunner H, Appenzeller S. Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cognitive-performance-score-of-the-pediatric-automated-neuropsychological-assessment-metrics-software-in-a-brazilian-cohort-and-its-association-with-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cognitive-performance-score-of-the-pediatric-automated-neuropsychological-assessment-metrics-software-in-a-brazilian-cohort-and-its-association-with-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology